MA53511A - Schéma de traitement en cas de doses oubliées pour des esters de palipéridone injectables à action prolongée - Google Patents
Schéma de traitement en cas de doses oubliées pour des esters de palipéridone injectables à action prolongéeInfo
- Publication number
- MA53511A MA53511A MA053511A MA53511A MA53511A MA 53511 A MA53511 A MA 53511A MA 053511 A MA053511 A MA 053511A MA 53511 A MA53511 A MA 53511A MA 53511 A MA53511 A MA 53511A
- Authority
- MA
- Morocco
- Prior art keywords
- acting
- injection
- long
- treatment regimen
- dose treatment
- Prior art date
Links
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical class FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 title 1
- 238000002347 injection Methods 0.000 title 1
- 239000007924 injection Substances 0.000 title 1
- 238000011269 treatment regimen Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562144054P | 2015-04-07 | 2015-04-07 | |
| PCT/US2016/024841 WO2016164218A1 (fr) | 2015-04-07 | 2016-03-30 | Schéma de traitement en cas de doses oubliées pour des esters de palipéridone injectables à action prolongée |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA53511A true MA53511A (fr) | 2021-09-15 |
| MA53511B1 MA53511B1 (fr) | 2023-12-29 |
Family
ID=89428893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA53511A MA53511B1 (fr) | 2015-04-07 | 2016-03-30 | Schéma de traitement en cas de doses oubliées pour des esters de palipéridone injectables à action prolongée |
Country Status (1)
| Country | Link |
|---|---|
| MA (1) | MA53511B1 (fr) |
-
2016
- 2016-03-30 MA MA53511A patent/MA53511B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA53511B1 (fr) | 2023-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3280416A4 (fr) | Schéma de traitement en cas de doses oubliées pour des esters de palipéridone injectables à action prolongée | |
| SI3936130T1 (sl) | Režim odmerjanja valbenazina za zdravljenje hiperkinetičnih gibalnih motenj | |
| IL263538A (en) | Radio-pharmaceutical complexes | |
| EP3413963A4 (fr) | Accès à un site de traitement intravasculaire | |
| EP4098297C0 (fr) | Dispositif d'obtention des doses pour seringues | |
| HUE062158T2 (hu) | EZH2 inhibitorok a limfóma kezelésére | |
| FR3016868B1 (fr) | Article a dose unitaire | |
| DK3272338T3 (da) | Oral doseringsform for ketamin | |
| EP3320521A4 (fr) | Indicateur thérapeutique atomique | |
| IL266171A (en) | Dosage and therapeutic regimen for hdm2-p53 interaction inhibitors | |
| IL247721A0 (en) | Pharmaceutical preparations containing active medicinal compounds for the treatment of solid tumors | |
| EP3217915C0 (fr) | Machine permettant de compter des articles médicaux et procédé correspondant | |
| DK3368017T3 (da) | Optimeret mesalazinholdig højdosistablet | |
| IL253439A0 (en) | Add-on radiosynthesiser device | |
| EP3432901A4 (fr) | Traitement anticancéreux séquentiel | |
| ZA201803010B (en) | Plasminogen dosage regimen for wound healing | |
| EP3395350A4 (fr) | Médicament pour le traitement des infarctus cérébraux | |
| MA53511A (fr) | Schéma de traitement en cas de doses oubliées pour des esters de palipéridone injectables à action prolongée | |
| MA41544A (fr) | Dosages de panobinostat pour le traitement du myélome multiple | |
| GB201614179D0 (en) | Dosage regimen for the treatment of endometriosis | |
| FR3024036B1 (fr) | Composes volatils pour le traitement du neuropaludisme | |
| GB201500383D0 (en) | Apparatus for treatment of radioactive materials | |
| IT201600129151U1 (it) | Contenitore antipuntura per aghi di siringhe usate | |
| TH1601003393A (th) | รูปแบบปริมาณที่ให้ทางเภสัชกรรม | |
| GB201600179D0 (en) | Apparatus for treatment of radioactive materials |